Back to Trials
NCT04295486PHASE2Recruiting

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

University of Miami

Start Date

3/1/2021

Completion Date

3/1/2027

Summary

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Eligibility Criteria

Age Range: 19 years to No maximum

Inclusion criteria: * \> 18 years of age * Planning to undergo a primary total hip or knee arthroplasty Exclusion Criteria: * High risk patients for VTE as defined by: * History of venous thromboembolism * Active malignancy * Known pro thrombotic condition * BMI \> 40 * Patients requiring anticoagulation for pre-existing conditions * Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others. * Patients not fluent in the language of the informed consent form * Prisoners * Pregnancy * Reported to have mental illness or belonging to a vulnerable population

Interventions

DRUG

Aspirin

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Venous Thromboembolism

Locations

University of Miami Hospital

Miami, Florida 33136

United States